Compare Amgen, Inc. (AMGN) vs CF Industries Holdings, Inc. (CF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs CF Industries Holdings, Inc. — how do they compare? Amgen, Inc. trades at $356.6 (market cap $196.12B), while CF Industries Holdings, Inc. trades at $121 (market cap $17.96B). The key difference: Amgen, Inc. is far larger — about 10.9× CF Industries Holdings, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CF | |
|---|---|---|
Market Cap | $196.12B | $17.96B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $137.55 |
52-Week Low | $271.18 | $76.08 |
Enterprise Value | $241.41B | $19.54B |
Dividend Yield | 2.77% | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CF Industries (CF) trades at $116.92, up 2.54% today, with strong bullish momentum from earnings beats and a 20% dividend increase announced July 8, 2026. The stock shows robust fundamentals with a P/E of 10.53 and ROE of 34.74%, while technical indicators signal bullish moving averages but overbought RSI levels near 76. Revenue growth rebounded to $7.08B in 2025 after a dip, supported by firm nitrogen demand.
Outlook remains positive with a consensus price target of $126.67, though risks include rising natural gas costs pressuring margins. The stock offers value and income appeal, but investors should monitor input cost trends and Q2 2026 earnings against expectations of $5.71 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →
